This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muralidharan, G.
Right arrow Articles by Troy, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muralidharan, G.
Right arrow Articles by Troy, S. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2005, p. 1656-1659, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1656-1659.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects

Gopal Muralidharan,1,{dagger} Richard J. Fruncillo,2 Marlynne Micalizzi,1 Donald G. Raible,1* and Steven M. Troy1

Wyeth Research, Collegeville,1 Wyeth Research Clinical Pharmacology Unit, Philadelphia, Pennsylvania2

Received 12 October 2004/ Returned for modification 29 November 2004/ Accepted 18 December 2004


arrow
ABSTRACT
 
The pharmacokinetics of tigecycline was evaluated in 46 healthy young and elderly men and women. Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters. Based on pharmacokinetics, no dosage adjustment is warranted based on age or sex.


arrow
TEXT
 
Tigecycline is a novel intravenously administered glycylcycline antibiotic exhibiting an expanded spectrum of in vitro and in vivo activity against gram-positive, gram-negative, atypical, anaerobic, and other difficult-to-treat pathogens (1-8, 10, 13, 18, 20-23, 25, 26). Clinical studies suggest that tigecycline is generally well tolerated and easy to use with a twice-daily dose regimen (17, 21). The clinical dosing regimen presently being evaluated is 100 mg followed by 50 mg every 12 h (17).

The primary objective of this open-label study was to determine if subject age or sex affects the pharmacokinetic profile of a single 100-mg intravenous dose of tigecycline, and the secondary objective was to compare the levels of observed open-label safety and tolerability of tigecycline among the age and sex groups.

Forty-six healthy men and women from the following three age categories were enrolled: young (18 to 50 years, inclusive), young-elderly (65 to 75 years, inclusive), and elderly (>75 years). Subjects were in good health on the basis of medical histories, physical examinations, electrocardiograms, and laboratory evaluations. The Institutional Review Board of The Methodist Hospital in Philadelphia, Pennsylvania approved the study, and all subjects gave written informed consent before enrollment. The demographic profile of each age-sex group is presented in Table 1.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Subject demographics

Tigecycline (100 mg) was administered as a single intravenous dose infused over 60 min. Serial blood samples for the determination of tigecycline concentrations in serum were collected over 120 h after the start of tigecycline infusion, and complete urine output was collected over 48 h after the start of the tigecycline infusion. Tigecycline concentrations in serum and urine were quantified by using validated analytical methods that are similar to those described previously (17).

Pharmacokinetic parameters based on serum data for tigecycline were estimated with standard noncompartmental methods (11) using a validated SAS (version 8.02) program. Pharmacokinetic parameters were compared among the age-sex groups by using a two-factor analysis of variance with factors for age, sex, and age-by-sex interaction.

Based on the intersubject variability observed in previous studies (17), it was estimated that having at least 20 subjects per sex and at least 17 in the younger cohort compared with the pooled elderly cohorts would provide a statistical power of at least 80% to detect a 30% difference for both the maximum concentrations of the drug in serum and the areas under the concentration-time curve (AUCs) between sexes or age groups.

Safety was evaluated from spontaneously reported signs and symptoms and from the results of physical examinations, including weight and height, vital sign measurements, 12-lead electrocardiograms, clinical laboratory evaluations (hematology and blood chemistry), and routine urinalyses. Adverse events were recorded throughout the study.

For the first 12 h after administration, tigecycline concentrations in serum were typically higher in women than in men for all age groups (Fig. 1). With the exception of the volumes of distribution at steady state (Vss), there were no other statistically significant differences in pharmacokinetic parameters among the age and sex groups (Table 2). Tigecycline Vss were large and approximated 350 liters (or 5.8 liters/kg of body weight) for women and 500 liters (or 6.2 liters/kg) for men. The difference in non-weight-normalized Vss between men and women attained statistical significance (P = 0.001), but the weight-normalized Vss did not differ significantly (P = 0.40), indicating that the observed differences were primarily caused by differences in body size between the men and women in this study.



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 1. Mean tigecycline concentrations in serum of subjects by age and sex group.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Pharmacokinetic parameters for tigecycline in young and elderly men and women

Tigecycline weight-normalized clearance was approximately 10% higher in young men than in young women (Table 2 and Fig. 2). The greatest between-sex difference for this parameter was the clearance in young-elderly women being 22% higher than that in young-elderly men; weight-normalized clearance among elderly women was 11% higher than that of their elderly male counterparts. None of these differences in weight-normalized clearance achieved statistical significance (Table 2).



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 2. Weight-normalized tigecycline clearances for individual subjects by age and sex group. {circ}, young women (18 to 50 years); •, young men (18 to 50 years); {triangleup}, young-elderly women (65 to 75 years); {blacktriangleup}, young-elderly men (65 to 75 years); {square}, elderly women (>75 years); {blacksquare}, elderly men (>75 years).

Mean tigecycline AUCs ranged from 4,218 ng · h/ml for the young men to 5,472 ng · h/ml for the elderly men. Mean AUC values for each of the three female age groups were approximately 5.1 to 5.3 µg · h/ml, compared with 4.2 to 5.5 µg · h/ml for men. In addition, tigecycline AUC values were approximately 21% higher for young women than for young men, whereas AUC values were only 4% higher for elderly women than for elderly men, which is consistent with the differences in clearances observed between groups.

One subject, a 46-year-old woman, withdrew from the study because of a rash that developed during the tigecycline infusion. This subject's vital sign data showed no evidence of a systemic allergic response, and the rash resolved in 12 h after the administration of diphenhydramine.

No serious adverse effects occurred during this study. Overall, tigecycline was reasonably well tolerated. Nine (36%) men and 16 (76%) women experienced one or more treatment-emergent adverse events (TEAEs). Most TEAEs were mild; two subjects reported nausea of moderate severity. The most common TEAE was nausea, which was more common in women (48%) than in men (24%). Only 1 (8%) of 13 subjects over 75 years of age reported nausea, compared with 4 of 15 (27%) subjects in the young-elderly group and 11 of 18 (61%) in the young age group. No clinically important changes in laboratory values or vital signs were observed during this study.

The aging process is known to affect the disposition of drugs by altering both body composition and organ function and, thus, may influence the pharmacokinetics of some drugs (9, 12, 14, 15, 19); these effects have been reviewed recently with respect to age (16) and sex (24). Overall, the results of this study demonstrate that the pharmacokinetic parameters of tigecycline do not differ significantly between sexes of the same age group or across age groups. Therefore, based upon pharmacokinetics, no dosage adjustment is necessary based on a patient's age or sex.


arrow
ACKNOWLEDGMENTS
 
This clinical study was supported by Wyeth Research, Collegeville, Pa.

We thank Scott A. Saunders for professional medical writing services in preparation of the manuscript.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Clinical Pharmacology Wyeth Research, 500 Arcola Rd., Collegeville, PA 19426. Phone: (484) 865-2519. Fax: (484) 865-9075. E-mail: RaibleD{at}wyeth.com. Back

{dagger} Present address: Lotus Labs Pvt. Ltd., Koramangala, Bangalore-560 095, India. Back


arrow
REFERENCES
 
    1
  1. Betriu, C., E. Culebras, I. Rodriguez-Avial, M. Gomez, B. A. Sanchez, and J. J. Picazo. 2004. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob. Agents Chemother. 48:323-325.[Abstract/Free Full Text]
    2. 2
  2. Betriu, C., I. Rodriguez-Avial, B. A. Sanchez, M. Gomez, J. Alvarez, J. J. Picazo, and the Spanish Group of Tigecycline. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46:892-895.[Abstract/Free Full Text]
    3. 3
  3. Biedenbach, D. J., M. L. Beach, and R. N. Jones. 2001. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn. Microbiol. Infect. Dis. 40:173-177.[CrossRef][Medline]
    4. 4
  4. Cazzola, M., F. Blasi, S. Centanni, C. F. Donner, and L. Allegra. 2001. Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections. Pulm. Pharmacol. Ther. 14:367-381.[CrossRef][Medline]
    5. 5
  5. Chopra, I. 2002. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist. Updates 5:119-125.[CrossRef][Medline]
    6. 6
  6. Deshpande, L. M., A. C. Gales, and R. N. Jones. 2001. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int. J. Antimicrob. Agents 18:29-35.[Medline]
    7. 7
  7. Edelstein, P. H., W. J. Weiss, and M. A. Edelstein. 2003. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 47:533-540.[Abstract/Free Full Text]
    8. 8
  8. Edlund, C., and C. E. Nord. 2000. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin. Microbiol. Infect. 6:159-163.[CrossRef][Medline]
    9. 9
  9. Hockings, N., A. A. Ajayi, and J. L. Reid. 1986. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br. J. Clin. Pharmacol. 21:341-348.[Medline]
    10. 10
  10. Jones, R. N. 1999. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn. Microbiol. Infect. Dis. 35:249-252.[CrossRef][Medline]
    11. 11
  11. Jusko, W. J. 1992. Guidelines for collection and analysis of pharmacokinetic data, p. 2-1-2-43. In W. E. Evans, J. J. Schentag, and W. J. Jusko (ed.), Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics, Vancouver, Wash.
    12. 12
  12. LaCreta, F. P., G. D. Kollia, G. Duncan, D. Behr, and D. M. Grasela. 2000. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 20:67S-75S.[CrossRef][Medline]
    13. 13
  13. Lefort, A., M. Lafaurie, L. Massias, Y. Petegnief, A. Saleh-Mghir, C. Muller-Serieys, D. Le Guludec, and B. Fantin. 2003. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47:216-222.[Abstract/Free Full Text]
    14. 14
  14. Meyers, B. R., and P. Wilkinson. 1989. Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage. Clin. Pharmacokinet. 17:385-395.[Medline]
    15. 15
  15. Muck, W., H. P. Breuel, and J. Kuhlmann. 1996. The influence of age on the pharmacokinetics of nimodipine. Int. J. Clin. Pharmacol. Ther. 34:293-298.[Medline]
    16. 16
  16. Muhlberg, W., and D. Platt. 1999. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45:243-253.[CrossRef][Medline]
    17. 17
  17. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.[Abstract/Free Full Text]
    18. 18
  18. Nannini, E. C., S. R. Pai, K. V. Singh, and B. E. Murray. 2003. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob. Agents Chemother. 47:529-532.[Abstract/Free Full Text]
    19. 19
  19. Norrby, S. R., and B. Ljungberg. 1989. Pharmacokinetics of fluorinated 4-quinolones in the aged. Rev. Infect. Dis. 11:S1102-S1106.
    20. 20
  20. Patel, R., M. S. Rouse, K. E. Piper, and J. M. Steckelberg. 2000. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:177-179.[CrossRef][Medline]
    21. 21
  21. Postier, R. G., S. L. Green, S. R. Klein, E. J. Ellis-Grosse, and E. Loh. 2004. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26:704-714.[CrossRef][Medline]
    22. 22
  22. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1994. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Chemother. 38:1658-1660.[Abstract/Free Full Text]
    23. 23
  23. Schnappinger, D., and W. Hillen. 1996. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch. Microbiol. 165:359-369.[CrossRef][Medline]
    24. 24
  24. Schwartz, J. B. 2003. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42:107-121.[CrossRef][Medline]
    25. 25
  25. Someya, Y., A. Yamaguchi, and T. Sawai. 1995. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob. Agents Chemother. 39:247-249.[Abstract]
    26. 26
  26. van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig, and O. Vesga. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, April 2005, p. 1656-1659, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1656-1659.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Starzengruber, P., Thriemer, K., Haque, R., Khan, W. A., Fuehrer, H. P., Siedl, A., Hofecker, V., Ley, B., Wernsdorfer, W. H., Noedl, H. (2009). Antimalarial Activity of Tigecycline, a Novel Glycylcycline Antibiotic. Antimicrob. Agents Chemother. 53: 4040-4042 [Abstract] [Full Text]  
  • Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Owen, J. S. (2007). Population Pharmacokinetics of Tigecycline in Healthy Volunteers. J Clin Pharmacol 47: 727-737 [Abstract] [Full Text]  
  • Slover, C. M, Rodvold, K. A, Danziger, L. H (2007). Tigecycline: A Novel Broad-Spectrum Antimicrobial. The Annals of Pharmacotherapy 41: 965-972 [Abstract] [Full Text]  
  • Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., Ellis-Grosse, E. J. (2006). Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58: 1221-1229 [Abstract] [Full Text]  
  • Van Wart, S. A., Owen, J. S., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Cirincione, B. B. (2006). Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 3701-3707 [Abstract] [Full Text]  
  • Agwuh, K. N., MacGowan, A. (2006). Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256-265 [Abstract] [Full Text]  
  • Thamlikitkul, V., Trakulsomboon, S. (2006). In Vitro Activity of Tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.. Antimicrob. Agents Chemother. 50: 1555-1557 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muralidharan, G.
Right arrow Articles by Troy, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muralidharan, G.
Right arrow Articles by Troy, S. M.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»